GLP-1 medications (like semaglutide and tirzepatide) were designed for metabolic disease, but they’ve become the headline in weight loss. The hype is real—appetite suppression, weight loss—but so are the nuances: side effects and cost. In clinic, the smartest results come from matching dose and schedule to the person. I adjust GLP-1 dosing for clients almost every day—not by mechanically stepping up per the label, but by making evidence-based tweaks  to match weight, body fat

In clinic, whenever coffee comes up, many people tense up. The same questions appear again and again: “Is it safe to drink coffee if I have a heart problem?” “If I don’t drink coffee I feel exhausted—should I force myself to quit?” It doesn’t help that media headlines often contradict one another. One day coffee is praised for lowering cancer risk and extending life; the next it’s labelled a trigger for high blood pressure and heart rhythm problems. No wonder so many people f

Why this lens (and how I arrived here) The single biggest turning point in my training came during a rotation at Weill Cornell’s pediatric endocrinology  service. In a center for pediatric obesity, I watched children and families change—not because of one prescription, but because their whole context  was addressed: food and sleep, movement and family systems, school and culture, even faith and community . When those elements lined up, outcomes were remarkable. I decided to d